We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI-Enhanced Wearables Could Transform Type 2 Diabetes and Prediabetes Care

By HospiMedica International staff writers
Posted on 02 Jan 2026

Artificial intelligence (AI)–powered wearable devices, particularly continuous glucose monitors, are rapidly changing how people with prediabetes and Type 2 diabetes understand and manage their blood sugar. More...

By collecting data every few minutes rather than a few times a day, these tools offer a far more detailed picture of glucose patterns. However, research in this area has been fragmented, often focusing on specific devices or AI models, making it difficult to assess the field as a whole.

To address this gap, researchers from the University at Buffalo (Buffalo, NY, USA) conducted the first comprehensive meta-review of AI-enhanced wearable technologies for prediabetes and Type 2 diabetes. Published in NPJ Digital Medicine, the study reviewed evidence from the past several years and concluded that while these devices hold enormous potential, important challenges must be resolved before they become routine tools in clinical care.

The research team analyzed 60 high-quality studies selected from nearly 5,000 peer-reviewed papers that examined the integration of artificial intelligence and wearable technology in diabetes management. The findings show that AI-enhanced wearables can predict glucose changes up to one to two hours in advance, allowing individuals to anticipate and avoid dangerous swings. These systems can also personalize guidance based on daily routines, physical activity, sleep patterns, and stress levels, while helping clinicians manage large volumes of patient data more efficiently.

Despite these advantages, the review highlights several limitations. Many AI systems operate as “black boxes,” providing predictions without explaining the underlying reasoning. This lack of transparency can make it difficult for patients and clinicians to trust or act on the recommendations. Other challenges include small and homogeneous study populations, limited external validation, the absence of standardized datasets, inconsistent data quality, and barriers related to cost and integration into existing clinical workflows.

The researchers also found that the performance of AI-enhanced wearables depends heavily on the type of AI model used. Time-series models such as long short-term memory networks are well-suited for continuous glucose data, while newer transformer-based models can integrate multiple data streams, including heart rate, sleep, and activity. However, simpler models may be easier to interpret and adopt in clinical settings, highlighting the need to balance performance with explainability.

Overall, the study suggests that AI-enhanced wearables could support earlier risk detection, more personalized care, and potentially delay progression from prediabetes to diabetes. However, broader validation, improved transparency, and better clinical integration will be essential before these technologies can reach their full potential.

“For people living with diabetes, AI-enabled wearables have the potential to provide more timely and personalized guidance, helping them avoid glucose swings and manage daily decisions with greater confidence,” said Raphael Fraser, PhD, corresponding author and associate professor of medicine. “For clinicians, the key takeaway is that these tools may help identify risks earlier and support more efficient care.”

Related Links:
University at Buffalo


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.